Convertible Senior Notes

Healthcare
Convertible Senior Notes

Summary

Baird served as co-manager on this transaction

About

AMAG Pharmaceuticals, Inc. (“AMAG” or the “Company”) (NASDAQ-GS: AMAG) recently priced an offering of $175 million aggregate principal amount of 2.50% Convertible Senior Notes due 2019. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

AMAG Pharmaceuticals is a rapidly growing, specialty pharmaceutical company, supported by a talented and passionate workforce. The company currently markets Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse in the United States. AMAG is headquartered in Waltham, Massachuesetts.

For additional information about this transaction, please contact:

David Schechner (617) 426-5424
Lance Lange (414) 765-7079
Ryan Mausehund (650) 858-3817
Manish Gupta (414) 765-3802
Satoshi Matsumoto (312) 609-5446
Healthcare
Convertible Senior Notes
Date
February 2014
Company
AMAG Pharmaceuticals, Inc.
Transaction
M&A
Sectors
Healthcare
Target Location
North America

Share